X0306 4 2019-01-03 0 0001437786 IMMUNE DESIGN CORP. IMDZ 0001606244 Paya Carlos V C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE WA 98102 1 1 0 0 President and CEO Common Stock 2019-01-03 4 A 0 63000 0.00 A 169590 D Common Stock 2019-01-07 4 S 0 13014 1.5822 D 156576 D Stock Option (right to buy) 1.31 2019-01-03 4 A 0 293000 0.00 A 2029-01-03 Common Stock 293000 293000 D Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. Restricted stock unit shall vest in a series of three equal consecutive annual installments beginning on January 4, 2020, subject to the Reporting Person's continuous service through each such date. The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2016, January 4, 2017 and January 4, 2018, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2019. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. One quarter of the shares underlying the option will vest on January 3, 2020, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date. /s/ Stephen R. Brady, Attorney-In-Fact 2019-01-07